Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
April 05, 2024 08:58 ET
|
PharmAla Biotech
PharmAla Biotech announces that its Australian Joint Venture, Cortexa, has initiated manufacturing of LaNeo MDMA in Australia.
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
March 27, 2024 08:00 ET
|
PharmAla Biotech
PharmAla recieves Allowance from USPTO for its lead drug candidate, a next-generation MDMA composition paving the way for clinical trials
PharmAla Biotech Signs Sale Agreement with Numinus
March 26, 2024 08:55 ET
|
PharmAla Biotech
PharmAla announces binding sales order from Numinus Wellness, as well as a recent presentation of data to the Behaviour, Biology, and Chemistry Conference
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
March 20, 2024 10:20 ET
|
PharmAla Biotech
PharmAla Recieves Notice of Allowance of Patent on Novel MDMA-like Molecule with improved safety, therapeutic range
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
March 18, 2024 08:55 ET
|
PharmAla Biotech
PharmAla's 50:50 Joint Venture with Vitura Health Limited, Cortexa, announces it is first entity to supply Psilocybin into Authorized Prescriber Scheme
PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update
March 08, 2024 16:15 ET
|
PharmAla Biotech
PharmAla provides corporate update following AGM
PharmAla named an Intellectual Property Ontario Client
February 22, 2024 08:55 ET
|
PharmAla Biotech
PharmAla recieves a non-dilutive grant from IP Ontario (IPON) to support its patent work in international markets.
PharmAla Data to be Published in ACS Chemical Neuroscience
February 20, 2024 08:55 ET
|
PharmAla Biotech
PharmAla's drug discovery data to be published in ACS Chemical Neuroscience; PharmAla presents data at ISRP Conference in New Orleans
PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development
February 09, 2024 08:10 ET
|
PharmAla Biotech
PharmAla signs all-cash agreement to consult for Red Light Holland
PharmAla releases Profitable Q1 Interim Financial Statement and Business Update
January 31, 2024 10:58 ET
|
PharmAla Biotech
PharmAla releases Profitable Q1 Interim Financial Statement, and will host investor webinar to discuss prominent changes to the business & FDA timelines